Two of a target of thirty-eight participants with chronic central serous chorioretinopathy will be enrolled initially. In this Phase II, single-center, placebo-controlled, double-masked, randomized trial, investigational product will be administered to two different groups. Half of the participants will be randomized to 5 mg oral finasteride for the initial three months. The other half of the participants will be randomized to placebo for the first three months. At the end of three months of treatment, all participants may be followed for at least four years and nine months. During this follow-up period, all participants will be able to receive finasteride therapy PRN if subretinal fluid re-emerges. The PRN phase will last until the last participant completes the five years of follow-up. Other standard care treatments, such as photodynamic therapy, will also be permitted after the primary outcome at three months.
|Nicholson, Benjamin; Noble, Jason; Forooghian, Farzin et al. (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103-26|
|Ardeljan, Daniel; Meyerle, Catherine B; Agron, Elvira et al. (2013) Influence of TIMP3/SYN3 polymorphisms on the phenotypic presentation of age-related macular degeneration. Eur J Hum Genet :|
|Dalal, Monica; Jacobs-El, Naima; Nicholson, Benjamin et al. (2013) Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:2705-9|